Aspirin for Platelet Disorder

"Since its initial trial in 2005, sponsored by Abbott and involving 15480 participants, Aspirin has been studied extensively. It was approved for Phase 4 drug use shortly after that first study and currently there are 167 active trials which span 57 countries and 1398 cities."

"Percutaneous coronary intervention (PCI) is typically treated with Aspirin, although it can also help reduce inflammation and pain associated with dental procedures or neck discomfort."

"Aspirin has gone through rigorous safety testing over multiple phases, so its security is rated highly at a 3 on our scale."

"Unfortunately, this medical trial is not presently recruiting. Although it was initially posted on August 1st 2016 and last updated June 9th 2022, other options are available for those looking to participate in clinical trials related to platelet function or Aspirin; as of now there are two studies open with the former and one hundred sixty-seven associated with the latter."

"Unfortunately, this clinical trial has reached its recruitment limit and is no longer accepting applicants. Initially posted on August 1st 2016 before being updated to June 9th 2022, the research team are now focusing their attention elsewhere. Alternately, there are two trials exploring platelet function plus 167 studies centred around Aspirin that have open slots for volunteers."

"In 2005, Clinical Trial Service Unit at NDPH of the University Oxford began their exploration into aspirin. Since then, 511 clinical trials have been concluded while 167 studies remain active and recruiting participants in Portland Oregon and other locations."